US Stock Insider Trading | ImmunityBio Discloses 4 Insider Transactions on February 12

K-LinePoet · 2026-03-08T02:25:33+00:00

ImmunityBio disclosed internal transactions on February 12, 2026, with four executives and major shareholders selling a total of approximately 212,200 shares on February 10, worth about $2,112,700. The company focuses on immunotherapy, dedicated to treating tumors and infectious diseases.

K-LinePoet

2026-03-08 02:25:33

Abstract generation in progress

On February 12, 2026, ImmunityBio (IBRX) disclosed four insider trading transactions. Director Richard Adcock sold 140,000 shares on February 10, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 12, 2026	Executive	LAUER REGAN J	February 10, 2026	Sell	2,257	6.93	$16,000
February 12, 2026	Shareholder with >10%	SOON-SHIONG PATRICK	February 10, 2026	Sell	118,600	6.93	$821,600
February 12, 2026	Executive	Sachs David C.	February 10, 2026	Sell	42,600	6.93	$295,500
February 12, 2026	Director	Adcock Richard	February 10, 2026	Sell	140,000	6.93	$970,500
January 21, 2026	Director	Selecky Christobel	January 20, 2026	Sell	25,000	7.51	$187,700
January 21, 2026	Director	Simon Barry J.	January 20, 2026	Sell	75,000	7.88	$590,900
January 21, 2026	Director	Selecky Christobel	January 20, 2026	Buy	75,000	2.98	$223,500
January 21, 2026	Director	Selecky Christobel	January 16, 2026	Sell	50,000	5.00	$250,000
January 21, 2026	Director	Simon Barry J.	January 20, 2026	Sell	77,000	6.54	$503,400
December 31, 2025	Director	Adcock Richard	December 31, 2025	Sell	17,500	1.98	$34,700

[Company Profile]

ImmunityBio, Inc. was incorporated on October 7, 2002, under the name ZelleRx Corporation in Illinois, and on January 22, 2010, the company was renamed Conkwest Inc. ImmunityBio is a leading late-stage immunotherapy company that activates innate and adaptive immune systems to address unmet needs in oncology and infectious diseases. The company is a leading manufacturer of ready-to-use natural killer (NK) cell therapies, including memory NK cells, along with a comprehensive platform of antibody-cytokine fusion proteins, albumin-binding immunomodulators, and vaccine vectors. By integrating these NK, macrophage, and T-cell activation platforms, the company believes ImmunityBio is at the forefront of immunotherapy, with late-stage clinical development across multiple tumor types and infectious diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes